PKD1 and metastatic melanoma: Since the E- to N-cadherin switch plays a critical role in the response to these therapies and in melanoma progression and based on our data from the present study, we propose the inhibition of PKD1 as a novel attractive approach for the treatment of metastatic melanoma that should be further tested in pre-clinical studies either alone or in combination with other therapies depending of the disease context.